Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2024-03-01 00:00:00 ET · period of report 2024-03-01 · accession 0001104659-24-030157 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-01 | 2024-03-01 | PTGX | Waddill William D. | Dir | S - Sale+OE | $31.34 | -13.0K | 12.0K | -52% | -$406.6K |
| D | 2024-03-01 | 2024-03-01 | PTGX | Waddill William D. | Dir | M - OptEx | $6.09 | +13.0K | 25.0K | +108% | +$79.0K |
| D | 2024-03-01 | 2024-03-01 | PTGX | Waddill William D. | Dir | M - OptEx | $0.00 | -13.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-01 | S | D | 12,975 | $31.34 | 12,000 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.46 to $31.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2024-03-01 | M | A | 12,975 | $6.09 | 24,975 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2024-03-01 | M | D | 12,975 | $0.00 | 0 | D | $6.09 · — to 2026-07-16 | 12,975 Common Stock | (F3) These stock options are fully vested. |